𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Reply: Huntington's disease and minocycline

✍ Scribed by Madhavi Thomas; Tetsuo Ashizawa; J. Jankovic

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
36 KB
Volume
20
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The original letter to which this reply refers was published in Movement DisordersMov Disord (2005) 20 (4) 510–511.

πŸ“œ SIMILAR VOLUMES

Huntington's disease and minocycline
Huntington's disease and minocycline
✍ Anna K. HΓΆdl; Raphael M. Bonelli πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 44 KB

## Abstract A reply to this letter has been published in __Movement__ DisordersMov Disord (2005) 20 (4) 511.

Minocycline in Huntington's disease: A p
Minocycline in Huntington's disease: A pilot study
✍ Madhavi Thomas; Tetsuo Ashizawa; Joseph Jankovic πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 62 KB πŸ‘ 1 views

## Abstract Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase (iNOS), and has been shown to delay disease progression in the mouse model R6/2 of Huntington's disease (HD). This safety and tolerability study included 30 patients with HD who were given minocycline over a 6

A futility study of minocycline in Hunti
A futility study of minocycline in Huntington's disease
✍ Dr. Merit Cudkowicz; The Huntington Study Group DOMINO Investigators πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 134 KB πŸ‘ 1 views

## Abstract This study assessed the futility of proceeding with a Phase 3 clinical trial of minocycline as a disease‐modifying treatment for Huntington's disease (HD). One hundred fourteen research participants with HD were randomized, 87 to minocycline (200 mg/d) and 27 to placebo. The change in T